The use of anti-C6VlsE in the assessment of the effectiveness of Lyme disease treatment – a preliminary report

• Autorzy: Shkilna M. , Tokarska-Rodak M. , Panczuk A. , Smiyan S. , Andreychyn M. , Klishch I. , Korda M.

Warianty tytułu

PL

Zastosowanie przeciwciał anty-C6VIsE w ocenie skuteczności leczenia boreliozy z Lyme – doniesienie wstępne

• Języki publikacji: EN

Abstrakty

EN

Background. The aim of this study was to evaluate the dynamics of changes in IgG anti-C6VlsE concentration in patients treated for Lyme borreliosis in relation to clinical manifestations of the disease. Material and methods. The study group consisted of 20 patients from Ternopil and surrounding areas (Western Ukraine) with clinical symptoms of Lyme borreliosis. IgG anti-C6VlsE was measured three times: before starting the patients on antibiotic therapy, immediately after its completion and 3-4 months after the end of antibiotic therapy. Results. In 40% of the patients the IgG anti-C6VlsE concentration decreased 3-4 months after the treatment, but only in half of them it was associated with elimination of symptoms. 60% of patients did not show any tendency to decrease in IgG anti-C6VlsE concentrations after 3-4 months after the treatment, and 25% of patients in this group had an improvement in health condition. Conclusions. It cannot be excluded that IgG anti-C6VlsE may be important in the serological evaluation of the efficacy of Lyme borreliosis treatment, especially in early stage patients. However, this requires further research, which should be extended to a larger group of patients. It is also important that the assessment of anti-C6VlsE antibody concentration should be performed additionally for a period longer than 4 months from the end of antibiotic therapy.

PL

Wprowadzenie. Celem badań była ocena dynamiki zmian stężenia IgG anty-C6VlsE u pacjentów leczonych w związku z boreliozą z Lyme w stosunku do manifestacji klinicznych choroby. Materiał i metody. Grupę badaną stanowiło 20 pacjentów z klinicznymi objawami boreliozy z Lyme z Tarnopola i okolic (Ukraina Zachodnia). IgG anty-C6VlsE oznaczano trzykrotnie: przed wdrożeniem antybiotykoterapii, bezpośrednio po jej zakończeniu i 3-4 miesiące od zakończenia antybiotykoterapii. Wyniki. U 40% badanych stwierdzono obniżenie stężenia IgG anty-C6VlsE po 3-4 miesiącach po leczeniu, przy czym tylko u połowy z nich wiązało się to z eliminacją dolegliwości. U 60% pacjentów nie stwierdzono tendencji obniżania stężeń IgG anty-C6VlsE po 3-4 miesiącach po leczeniu, a u 25% tej grupy nastąpiła poprawa stanu zdrowia. Wnioski. Nie wykluczone, że IgG anty-C6VlsE może mieć znaczenie w serologicznej ocenie skuteczności leczenia boreliozy z Lyme, zwłaszcza u osób we wczesnym okresie choroby. Wymaga to jednak dalszych badań, którymi należałoby objąć liczniejszą grupę pacjentów. Istotne jest także, by ocena stężenia przeciwciał anty-C6VlsE dokonywana była dodatkowo w okresie dłuższym niż 4 miesiące od zakończenia antybiotykoterapii.

Słowa kluczowe

EN

Ukraine; human disease; treatment; Lyme disease; antigen; effectiveness; disease treatment

• Wydawca: -
• Czasopismo: Health Problems of Civilization
• Rocznik: 2019
• Tom: 13
• Numer: 1
• Opis fizyczny: p.83-91,ref.

Twórcy

autor

Shkilna M.

• Ivan Horbachevsky Ternopil State Medical University, Ternopil, Ukraine

autor

Tokarska-Rodak M.

• Institute of Health Sciences, Pope John Paul II State School of Higher Education, Sidorska 95/97, 21-500 Biala Podlaska, Poland

autor

Panczuk A.

• Institute of Physical Education and Physiotherapy, Pope John Paul II State School of Higher Education in Biala Podlaska, Biala Podlaska, Poland

autor

Smiyan S.

• Ivan Horbachevsky Ternopil State Medical University, Ternopil, Ukraine

autor

Andreychyn M.

• Ivan Horbachevsky Ternopil State Medical University, Ternopil, Ukraine

autor

Klishch I.

• Ivan Horbachevsky Ternopil State Medical University, Ternopil, Ukraine

autor

Korda M.

• Ivan Horbachevsky Ternopil State Medical University, Ternopil, Ukraine

Bibliografia

• 1. Leeflang MMG, Ang CW, Berkhout J, Bijlmer HA, Van Bortel W, Brandenburg AH, et al. The diagnostic accuracy of serological tests for Lyme borreliosis in Europe: a systematic review and meta-analysis. BMC Infectious Diseases. 2016; 16: 140. https://doi.org/10.1186/s12879-016-1468-4
• 2. Marangoni A, Sambri V, Accardo S, Cavrini F, Mondardini V, Moroni A, et al. A decrease in the immunoglobulin G antibody response against the VlsE protein of Borrelia burgdorferi Sensu Lato correlates with the resolution of clinical signs in antibiotic-treated patients with early Lyme disease. Clin Vaccine Immunol. 2006; 13(4): 525–529. https://doi.org/10.1128/CVI.13.4.525-529.2006
• 3. Chmielewski T, Dunaj J, Gołąb E, Gut W, Horban A, Pancewicz S, et al. [Laboratory diagnostics of tick-borne diseases. Working Group Recommendations] [Internet]. Warszawa; 2014 [cited 2018 March 02]; [about 1–50 p.]. Available from: http://kidl.org.pl/uploads/rekomendacje/05_kleszcze%20z%20okladka.pdf (in Polish).
• 4. Hofmann H. The variable spectrum of cutaneous L yme borreliosis. Diagnosis and therapy. Hautarzt. 2012; 63(5): 381-9. https://doi.org/10.1007/s00105-011-2256-0
• 5. Flisiak R, Pancewicz S. [Diagnostics and treatment of Lyme borreliosis. Recommendations of Polish Society of Epidemiology and Infectious Diseases] [Internet]. Białystok: Klinika Chorób Zakaźnych i Hepatologii UM; 2011 [cited 2018 March 02]. Available from: http://www.pteilchz.org.pl/ (in Polish).
• 6. Krzemień PJ. Role of VlsE/C6 antigen as a marker for early Lyme borreliosis diagnosis and monitoring the effectiveness of its treatment. Health Prob Civil. 2017; 11(2): 87-92. https://doi.org/10.5114/hpc.2017.69023
• 7. Embers ME, Jacobs MB, Johnson BJB, Philipp MT. Dominant epitopes of the C6 diagnostic eptide of Borrelia burgdorferi are largely inaccessible to antibody on the parent VlsE molecule. Clin Vaccine Immunol. 2007; 14(8): 931-936. https://doi.org/10.1128/CVI.00075-07
• 8. Pancewicz SA, Garlicki AM, Moniuszko-Malinowska A, Zajkowska J, Kondrusik M, Grygorczuk S, et al. [Diagnostics and treatment of tick-transmitted diseases. Recommendations of Polish Society of Epidemiology and Infectious Diseases]. Przegl Epidemiol. 2015; 69: 421 – 428 (in Polish).
• 9. Philipp MT, Wormser GP, Marques AR, Bittker S, Martin DS, Nowakowski J, et al. A decline in C6 antibody titer occurs in successfully treated patients with culture-confirmed early localized or early disseminated Lyme Borreliosis. Clin Diagn Lab Immunol. 2005; 12(9): 1069–1074. https://doi.org/10.1128/CDLI.12.9.1069-1074.2005
• 10. Stanek G, Fingerle V, Hunfeld KP, Jaulhac B, Kaiser R, Krause A, et al. Lyme borreliosis: clinical case definitions for diagnosis and management in Europe. Clin Microbiol Infect. 2011; 17(1): 69-79. https://doi.org/10.1111/j.1469-0691.2010.03175.x
• 11. Philipp MT, Bowers LC, Fawcett PT, Jacobs MB, Liang FT, Marques AR, et al. Antibody response to IR6, a conserved immunodominant region of the VlsE lipoprotein, wanes rapidly after antibiotic treatment of Borrelia burgdorferi infection in experimental animals and in humans. J Infect Dis. 2001; 184(7): 870–878. https://doi.org/10.1086/323392
• 12. Fleming RV, Marques AR, Klempner MS, Schmid CH, Dally LG, Martin DS, et al. Pre-treatment and posttreatment assessment of the C(6) test in patients with persistent symptoms and a history of Lyme borreliosis. Eur J Clin Microbiol Infect Dis. 2004; 23(8): 615-8. https://doi.org/10.1007/s10096-004-1163-z

Identyfikatory

DOI

10.5114/hpc.2019.81106